Neuroscience
From the AP, via The WashingtonPost.com website, concerning glial cell line-derived neurotrophic factor (GDNF):
-
Anthony H. Risser
neuroscience | neuropsychology | brain | parkinson disease
- Rasagiline And Parkinson's Disease
From the FDA on the 17th of May: FDA Approves New Treatment for Parkinson's Disease The Food and Drug Administration today approved Azilect (rasagiline), a new molecular entity, for the treatment of Parkinson's disease. The drug is a monoamine...
- Parkinson Disease, Creatine, And Minocycline
From an NIH new release: Preliminary Study Shows Creatine and Minocycline May Warrant Further Study In Parkinson’s Disease A National Institutes of Health-sponsored clinical trial with 200 Parkinson's disease patients has shown...
- Business World: Acadia Pharm, Acp-103, & Parkinson Disease
From an AP report posted at Yahoo!: Acadia Pharma Says Drug Study Encouraging Wednesday June 22, 7:44 pm ET Acadia Pharmaceuticals Says Lead Drug Helped Psychosis in Parkinson's Patients; Shares Fall SAN DIEGO (AP) -- Acadia Pharmaceuticals Inc....
- In The Weeklies
This week's issue of the New England Journal of Medicine (09 December 2004) includes two research papers and one editorial comment on topics concerning Parkinson disease: Levodopa and the Progression of Parkinson's Disease by The Parkinson...
- Issues In Clinical Trials: Gdnf And Parkinson Disease
Today's New York Times includes a front-page article about the culture of clinical-trials research: what happens to participant subjects when an experimental drug is pulled from testing and, among other issues, how teasing apart placebo-based from...
Neuroscience
Amgen's GDNF and Parkinson Disease
From the AP, via The WashingtonPost.com website, concerning glial cell line-derived neurotrophic factor (GDNF):
Autopsy Shows Parkinson's Drug's Progress[ ... Read the full article ... ]
By RANDOLPH E. SCHMID
The Associated Press
Friday, July 1, 2005; 3:57 PM
WASHINGTON -- A drug withdrawn from clinical trials because of safety concerns was helping regrow nerve fibers in the brain of a man with Parkinson's disease, scientists report.
The finding probably will renew debate over the drug, GDNF. It had offered encouragement to people with Parkinson's who reported improvement when using it in trials. But the drug was withdrawn by the manufacturer, Amgen, this year.
Some of those patients in the trial sued Amgen to get continued supplies of the drug. They were turned down by a federal judge in New York in June. A second suit is pending.
Seth Love, Steven S. Gill and colleagues at Frenchay Hospital in Bristol, England, report in Monday's issue of the journal Nature Medicine that an autopsy of the brain of one of the patients who received the drug in an early trial shows that nerve fibers that are lost in the disease were growing back.
-
Anthony H. Risser
neuroscience | neuropsychology | brain | parkinson disease
- Rasagiline And Parkinson's Disease
From the FDA on the 17th of May: FDA Approves New Treatment for Parkinson's Disease The Food and Drug Administration today approved Azilect (rasagiline), a new molecular entity, for the treatment of Parkinson's disease. The drug is a monoamine...
- Parkinson Disease, Creatine, And Minocycline
From an NIH new release: Preliminary Study Shows Creatine and Minocycline May Warrant Further Study In Parkinson’s Disease A National Institutes of Health-sponsored clinical trial with 200 Parkinson's disease patients has shown...
- Business World: Acadia Pharm, Acp-103, & Parkinson Disease
From an AP report posted at Yahoo!: Acadia Pharma Says Drug Study Encouraging Wednesday June 22, 7:44 pm ET Acadia Pharmaceuticals Says Lead Drug Helped Psychosis in Parkinson's Patients; Shares Fall SAN DIEGO (AP) -- Acadia Pharmaceuticals Inc....
- In The Weeklies
This week's issue of the New England Journal of Medicine (09 December 2004) includes two research papers and one editorial comment on topics concerning Parkinson disease: Levodopa and the Progression of Parkinson's Disease by The Parkinson...
- Issues In Clinical Trials: Gdnf And Parkinson Disease
Today's New York Times includes a front-page article about the culture of clinical-trials research: what happens to participant subjects when an experimental drug is pulled from testing and, among other issues, how teasing apart placebo-based from...